Lb Pharmaceuticals (LBRX) Operating Expenses (2024 - 2026)

Lb Pharmaceuticals' Operating Expenses history runs 3 years deep, the most recent figure standing at $22.1 million for Q1 2026.

• In Q1 2026, Operating Expenses rose 243.82% year-over-year to $22.1 million; the TTM figure through Mar 2026 stood at $47.6 million (changed N/A YoY), while the FY2025 annual figure was $30.4 million, down 53.1% from the prior year.
• Operating Expenses for Q1 2026 stood at $22.1 million, up from $13.9 million in the prior quarter.
• The five-year high for Operating Expenses was $22.1 million in Q1 2026, with the low at $5.2 million in Q3 2025.
• The 3-year median for Operating Expenses is $10.1 million (2025), against an average of $11.5 million.
• The sharpest annual moves came in 2025 and 2026: Operating Expenses tumbled 67.38% in 2025, then soared 243.82% in 2026.
• Lb Pharmaceuticals' Operating Expenses stood at $5.5 million in 2024, then soared by 150.41% to $13.9 million in 2025, then soared by 59.37% to $22.1 million in 2026.
• Business Quant data shows LBRX's Operating Expenses at $22.1 million in Q1 2026, $13.9 million in Q4 2025, and $5.2 million in Q3 2025.